Use of Imaging to Select Patients for Late Window Endovascular Therapy

DAWN indicates Triage of Wake-up and Late Presenting Strokes Undergoing Neurointervention With Trevo); DEFUSE 3, Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3; ICA, internal carotid artery; M1, the first segment of the middle cerebral artery; and NIHSS, National Institutes of Health Stroke Scale.

CTP indicates computed tomography perfusion; DAWN, Triage of Wake-up and Late Presenting Strokes Undergoing Neurointervention With Trevo; DEFUSE 3, Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; and SWIFT PRIME, Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke.
*SWIFT PRIME was an early window (<6 hours) study.
†CTP and MRI groups had statistically significant treatment effects on the studies primary outcome.
‡DAWN reported pooled data for the thrombectomy and control arms for the MRI and CTP subgroups.

Authors and Disclosures

Gregory W. Albers, MD

Department of Neurology and Neurological Sciences, Stanford University Medical Center, Stanford Stroke Center, Palo Alto, CA.

Correspondence to
Gregory W. Albers, MD, Stanford Stroke Center, 780 Welch Rd, Suite 350, Palo Alto, CA 94035. Email albers@stanford.edu

Disclosures
Dr Albers has an equity interest in iSchemaView and is a consultant for iSchemaView, Medtronic and Genentech. DEFUSE 3 was funded by the National Institutes of Health (Principal Investigator, Dr Albers).